Skip to main content
Top
Published in: Trials 1/2018

Open Access 01-12-2018 | Review

Application of causal inference methods in the analyses of randomised controlled trials: a systematic review

Authors: Ruth E. Farmer, Daphne Kounali, A. Sarah Walker, Jelena Savović, Alison Richards, Margaret T. May, Deborah Ford

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Applications of causal inference methods to randomised controlled trial (RCT) data have usually focused on adjusting for compliance with the randomised intervention rather than on using RCT data to address other, non-randomised questions. In this paper we review use of causal inference methods to assess the impact of aspects of patient management other than the randomised intervention in RCTs.

Methods

We identified papers that used causal inference methodology in RCT data from Medline, Premedline, Embase, Cochrane Library, and Web of Science from 1986 to September 2014, using a forward citation search of five seminal papers, and a keyword search. We did not include studies where inverse probability weighting was used solely to balance baseline characteristics, adjust for loss to follow-up or adjust for non-compliance to randomised treatment. Studies where the exposure could not be assigned were also excluded.

Results

There were 25 papers identified. Nearly half the papers (11/25) estimated the causal effect of concomitant medication on outcome. The remainder were concerned with post-randomisation treatment regimens (sequential treatments, n =5 ), effects of treatment timing (n = 2) and treatment dosing or duration (n = 7). Examples were found in cardiovascular disease (n = 5), HIV (n = 7), cancer (n = 6), mental health (n = 4), paediatrics (n = 2) and transfusion medicine (n = 1). The most common method implemented was a marginal structural model with inverse probability of treatment weighting.

Conclusions

Examples of studies which exploit RCT data to address non-randomised questions using causal inference methodology remain relatively limited, despite the growth in methodological development and increasing utilisation in observational studies. Further efforts may be needed to promote use of causal methods to address additional clinical questions within RCTs to maximise their value.
Appendix
Available only for authorised users
Literature
1.
go back to reference Robins J. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. Math Model. 1986;7(9):1393–512.CrossRef Robins J. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. Math Model. 1986;7(9):1393–512.CrossRef
2.
go back to reference Robins JM, et al. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology. 1992;3(4):319–36.CrossRefPubMed Robins JM, et al. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology. 1992;3(4):319–36.CrossRefPubMed
3.
go back to reference Robins JM, Hernán M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–60.CrossRefPubMed Robins JM, Hernán M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–60.CrossRefPubMed
4.
go back to reference Cole SR, et al. Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death. Am J Epidemiol. 2012;175(5):381–90. Erratum in Am J Epidemiol. 2012 Apr 1;175(7):732.CrossRefPubMedPubMedCentral Cole SR, et al. Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death. Am J Epidemiol. 2012;175(5):381–90. Erratum in Am J Epidemiol. 2012 Apr 1;175(7):732.CrossRefPubMedPubMedCentral
5.
go back to reference Hernán MA, et al. Observational studies analyzed like randomized experiments an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766–79.CrossRefPubMedPubMedCentral Hernán MA, et al. Observational studies analyzed like randomized experiments an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766–79.CrossRefPubMedPubMedCentral
6.
go back to reference Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96(454):440–8.CrossRef Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96(454):440–8.CrossRef
7.
go back to reference Hernán MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med. 2002;21(12):1689–709.CrossRefPubMed Hernán MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med. 2002;21(12):1689–709.CrossRefPubMed
8.
go back to reference Hernandez D, et al. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrol Dial Transplant. 2012;27(1):417–22.CrossRefPubMed Hernandez D, et al. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrol Dial Transplant. 2012;27(1):417–22.CrossRefPubMed
9.
go back to reference Hernán M, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561–70.CrossRefPubMed Hernán M, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561–70.CrossRefPubMed
10.
go back to reference Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779–88.CrossRefPubMed Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779–88.CrossRefPubMed
11.
go back to reference Toh S, et al. Estimating absolute risks in the presence of nonadherence an application to a follow-up study with baseline randomization. Epidemiology. 2010;21(4):528–39.CrossRefPubMedPubMedCentral Toh S, et al. Estimating absolute risks in the presence of nonadherence an application to a follow-up study with baseline randomization. Epidemiology. 2010;21(4):528–39.CrossRefPubMedPubMedCentral
12.
go back to reference Naimi AI, Cole SR, Kennedy EH. An introduction to g methods. Int J Epidemiol. 2017;46(2):756–62.PubMed Naimi AI, Cole SR, Kennedy EH. An introduction to g methods. Int J Epidemiol. 2017;46(2):756–62.PubMed
13.
go back to reference Daniel RM, et al. Methods for dealing with time-dependent confounding. Stat Med. 2013;32(9):1584–618.CrossRefPubMed Daniel RM, et al. Methods for dealing with time-dependent confounding. Stat Med. 2013;32(9):1584–618.CrossRefPubMed
15.
go back to reference Robins JM. Association, causation, and marginal structural models. Synthese. 1999;121(1-2):151–79.CrossRef Robins JM. Association, causation, and marginal structural models. Synthese. 1999;121(1-2):151–79.CrossRef
16.
go back to reference Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J. 2009;339:b2535.CrossRef Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J. 2009;339:b2535.CrossRef
17.
go back to reference Crook AM, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod. 2014;29(8):1810–7.CrossRefPubMedPubMedCentral Crook AM, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod. 2014;29(8):1810–7.CrossRefPubMedPubMedCentral
18.
go back to reference Morrison CS, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26(4):497–504.CrossRefPubMed Morrison CS, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26(4):497–504.CrossRefPubMed
19.
go back to reference McCoy SI, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS. 2013;27(6):1001–9.CrossRefPubMed McCoy SI, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS. 2013;27(6):1001–9.CrossRefPubMed
20.
go back to reference Rosenblum M, et al. Analysing direct effects in randomized trials with secondary interventions: an application to human immunodeficiency virus prevention trials. J R Stat Soc Ser A Stat Soc. 2009;172:443–65.CrossRefPubMedPubMedCentral Rosenblum M, et al. Analysing direct effects in randomized trials with secondary interventions: an application to human immunodeficiency virus prevention trials. J R Stat Soc Ser A Stat Soc. 2009;172:443–65.CrossRefPubMedPubMedCentral
21.
go back to reference Walker AS, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375(9722):1278–86.CrossRefPubMedPubMedCentral Walker AS, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375(9722):1278–86.CrossRefPubMedPubMedCentral
22.
go back to reference Alexander JH, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014;35(4):224–32.CrossRefPubMed Alexander JH, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014;35(4):224–32.CrossRefPubMed
23.
go back to reference Kataoka Y, et al. Effects of Voglibose and Nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J. 2012;76(3):712–20.CrossRefPubMed Kataoka Y, et al. Effects of Voglibose and Nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J. 2012;76(3):712–20.CrossRefPubMed
24.
go back to reference Shen L, et al. Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347:f6745.CrossRefPubMedPubMedCentral Shen L, et al. Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347:f6745.CrossRefPubMedPubMedCentral
25.
go back to reference Zhang Y, et al. Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy. Is adding drugs always beneficial? J Hypertens. 2012;30(11):2202–12.CrossRefPubMed Zhang Y, et al. Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy. Is adding drugs always beneficial? J Hypertens. 2012;30(11):2202–12.CrossRefPubMed
26.
go back to reference Bobo WV, et al. Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial. J Affect Disord. 2014;161:30–5.CrossRefPubMedPubMedCentral Bobo WV, et al. Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial. J Affect Disord. 2014;161:30–5.CrossRefPubMedPubMedCentral
27.
go back to reference Shinozaki T, et al. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model. Geriatr Gerontol Int. 2012;12(1):88–102.CrossRefPubMed Shinozaki T, et al. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model. Geriatr Gerontol Int. 2012;12(1):88–102.CrossRefPubMed
28.
go back to reference Wang L, et al. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc. 2012;107(498):493–508.CrossRefPubMedPubMedCentral Wang L, et al. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc. 2012;107(498):493–508.CrossRefPubMedPubMedCentral
29.
go back to reference Murphy SA. Optimal dynamic treatment regimes. J R Stat Soc Ser B Stat Methodol. 2003;65:331–55.CrossRef Murphy SA. Optimal dynamic treatment regimes. J R Stat Soc Ser B Stat Methodol. 2003;65:331–55.CrossRef
30.
go back to reference van der Laan MJ, Petersen ML. Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat. 2007;3(1):Article3.PubMedCentral van der Laan MJ, Petersen ML. Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat. 2007;3(1):Article3.PubMedCentral
31.
go back to reference Wahed AS, Thall PF. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukaemia. J R Stat Soc: Ser C: Appl Stat. 2013;62(1):67–83.CrossRef Wahed AS, Thall PF. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukaemia. J R Stat Soc: Ser C: Appl Stat. 2013;62(1):67–83.CrossRef
32.
go back to reference Yamaguchi T, Ohashi Y. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer. Stat Med. 2004;23(13):2005–22.CrossRefPubMed Yamaguchi T, Ohashi Y. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer. Stat Med. 2004;23(13):2005–22.CrossRefPubMed
33.
go back to reference Zhang M, Whang YP. Adjusting for observational secondary treatments in estimating the effects of randomized treatments. Biostatistics. 2013;14(3):491–501. Zhang M, Whang YP. Adjusting for observational secondary treatments in estimating the effects of randomized treatments. Biostatistics. 2013;14(3):491–501.
34.
go back to reference London WB, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010;28(24):3808–15.CrossRefPubMedPubMedCentral London WB, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010;28(24):3808–15.CrossRefPubMedPubMedCentral
35.
go back to reference Robins JM. Optimal structural nested models for optimal sequential decisions. In: Lin DY, Heagerty PJ, editors. Proceedings of the Second Seattle Symposium in Biostatistics: analysis of correlated data. New York: Springer New York; 2004. p. 189–326.CrossRef Robins JM. Optimal structural nested models for optimal sequential decisions. In: Lin DY, Heagerty PJ, editors. Proceedings of the Second Seattle Symposium in Biostatistics: analysis of correlated data. New York: Springer New York; 2004. p. 189–326.CrossRef
36.
go back to reference Li L, et al. Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: results from the AIDS Clinical Trials Group Study A5095. J Am Stat Assoc. 2012;107(498):542–54.CrossRefPubMedPubMedCentral Li L, et al. Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: results from the AIDS Clinical Trials Group Study A5095. J Am Stat Assoc. 2012;107(498):542–54.CrossRefPubMedPubMedCentral
38.
go back to reference Shortreed SM, Moodie EEM. Estimating the optimal dynamic antipsychotic treatment regime: evidence from the sequential multiple-assignment randomized Clinical Antipsychotic Trials of Intervention and Effectiveness schizophrenia study. J R Stat Soc: Ser C: Appl Stat. 2012;61:577–99.CrossRef Shortreed SM, Moodie EEM. Estimating the optimal dynamic antipsychotic treatment regime: evidence from the sequential multiple-assignment randomized Clinical Antipsychotic Trials of Intervention and Effectiveness schizophrenia study. J R Stat Soc: Ser C: Appl Stat. 2012;61:577–99.CrossRef
39.
go back to reference Rosthøj S, Keiding N, Schmiegelow K. Estimation of dynamic treatment strategies for maintenance therapy of children with acute lymphoblastic leukaemia: an application of history-adjusted marginal structural models. Stat Med. 2012;31(5):470–88. Rosthøj S, Keiding N, Schmiegelow K. Estimation of dynamic treatment strategies for maintenance therapy of children with acute lymphoblastic leukaemia: an application of history-adjusted marginal structural models. Stat Med. 2012;31(5):470–88.
40.
go back to reference van der Laan Mark J, Petersen Maya L, Joffe Marshall M. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens. Int J Biostat. 2005;1(1):Article 4. van der Laan Mark J, Petersen Maya L, Joffe Marshall M. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens. Int J Biostat. 2005;1(1):Article 4.
41.
go back to reference Lipkovich I, et al. Evaluating dose response from flexible dose clinical trials. BMC Psychiatry. 2008;8(1):1–9.CrossRef Lipkovich I, et al. Evaluating dose response from flexible dose clinical trials. BMC Psychiatry. 2008;8(1):1–9.CrossRef
42.
go back to reference Severus WE, et al. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry. 2010;25(8):443–9.CrossRefPubMed Severus WE, et al. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry. 2010;25(8):443–9.CrossRefPubMed
43.
go back to reference Cook RJ, et al. Inverse probability weighted estimating equations for randomized trials in transfusion medicine. Stat Med. 2013;32(25):4380–99.CrossRefPubMed Cook RJ, et al. Inverse probability weighted estimating equations for randomized trials in transfusion medicine. Stat Med. 2013;32(25):4380–99.CrossRefPubMed
44.
go back to reference Vandebosch A, Goetghebeur E, Van Damme L. Structural accelerated failure time models for the effects of observed exposures on repeated events in a clinical trial. Stat Med. 2005;24(7):1029–46.CrossRefPubMed Vandebosch A, Goetghebeur E, Van Damme L. Structural accelerated failure time models for the effects of observed exposures on repeated events in a clinical trial. Stat Med. 2005;24(7):1029–46.CrossRefPubMed
45.
go back to reference Platt RW, et al. An information criterion for marginal structural models. Stat Med. 2013;32(8):1383–93.CrossRefPubMed Platt RW, et al. An information criterion for marginal structural models. Stat Med. 2013;32(8):1383–93.CrossRefPubMed
46.
go back to reference Moodie EEM, Platt RW, Kramer MS. Estimating response-maximized decision rules with applications to breastfeeding. J Am Stat Assoc. 2009;104(485):155–65.CrossRef Moodie EEM, Platt RW, Kramer MS. Estimating response-maximized decision rules with applications to breastfeeding. J Am Stat Assoc. 2009;104(485):155–65.CrossRef
47.
go back to reference Ford D, et al. The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models. Am J Epidemiol. 2015;182(7):633–43.CrossRefPubMedPubMedCentral Ford D, et al. The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models. Am J Epidemiol. 2015;182(7):633–43.CrossRefPubMedPubMedCentral
48.
go back to reference Zietemann VD, Schuster T, Duell THG. Post study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. J Thorac Dis. 2011;3:88–98.PubMedPubMedCentral Zietemann VD, Schuster T, Duell THG. Post study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. J Thorac Dis. 2011;3:88–98.PubMedPubMedCentral
49.
go back to reference Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran ME, Berry D, editors. Statistical models in epidemiology: the environment and clinical trials. New York: Springer-Verlag; 1999. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran ME, Berry D, editors. Statistical models in epidemiology: the environment and clinical trials. New York: Springer-Verlag; 1999.
50.
go back to reference Robins JM, Greenland S. Adjusting for differential rates of prophylaxis therapy for PCP in high-dose versus low-dose AZT treatment arms in an AIDS randomized trial. J Am Stat Assoc. 1994;89(427):737–49.CrossRef Robins JM, Greenland S. Adjusting for differential rates of prophylaxis therapy for PCP in high-dose versus low-dose AZT treatment arms in an AIDS randomized trial. J Am Stat Assoc. 1994;89(427):737–49.CrossRef
51.
go back to reference Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95.CrossRefPubMed Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95.CrossRefPubMed
52.
go back to reference Shen L, et al. Do diuretics, beta-blockers, and statins increase the risk of diabetes in patients with impaired glucose tolerance? Insights from the NAVIGATOR study. Circulation. 2012;126:A14642. Shen L, et al. Do diuretics, beta-blockers, and statins increase the risk of diabetes in patients with impaired glucose tolerance? Insights from the NAVIGATOR study. Circulation. 2012;126:A14642.
53.
go back to reference Hernán MA, et al. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf. 2005;14(7):477–91.CrossRefPubMed Hernán MA, et al. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf. 2005;14(7):477–91.CrossRefPubMed
54.
go back to reference Cain LE, et al. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat. 2010;6(2):18.CrossRefPubMedCentral Cain LE, et al. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat. 2010;6(2):18.CrossRefPubMedCentral
55.
go back to reference Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory and Methods. 1991;20(8):2609–31.CrossRef Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory and Methods. 1991;20(8):2609–31.CrossRef
56.
go back to reference Robins JM, Rotnitzky A. Recovery of information and adjustment for dependent censoring using surrogate markers. In: Jewell NP, Dietz K, Farewell VT, editors. AIDS epidemiology: methodological issues. Boston: Birkhäuser Boston; 1992. p. 297–331.CrossRef Robins JM, Rotnitzky A. Recovery of information and adjustment for dependent censoring using surrogate markers. In: Jewell NP, Dietz K, Farewell VT, editors. AIDS epidemiology: methodological issues. Boston: Birkhäuser Boston; 1992. p. 297–331.CrossRef
57.
go back to reference Zhang M, Wang Y. Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment. Biostatistics. 2012;13(4):625–36.CrossRefPubMed Zhang M, Wang Y. Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment. Biostatistics. 2012;13(4):625–36.CrossRefPubMed
58.
go back to reference Robins JM. Structural nested failure time models. Wiley StatsRef: statistics reference online. 2014. Robins JM. Structural nested failure time models. Wiley StatsRef: statistics reference online. 2014.
59.
go back to reference Robins JM. Correcting for noncompliance in randomized trials using structural nested mean models. Commun Stat Theory and Methods. 1994;23(8):2379–412.CrossRef Robins JM. Correcting for noncompliance in randomized trials using structural nested mean models. Commun Stat Theory and Methods. 1994;23(8):2379–412.CrossRef
Metadata
Title
Application of causal inference methods in the analyses of randomised controlled trials: a systematic review
Authors
Ruth E. Farmer
Daphne Kounali
A. Sarah Walker
Jelena Savović
Alison Richards
Margaret T. May
Deborah Ford
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-017-2381-x

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue